Home/ Stocks/ LGVN

Longeveron Inc. Common Stock

LGVN XNAS

$0.85 -0.02 (-1.91%) ▼ 15-min delayed

Open

$0.87

High

$0.88

Low

$0.84

Volume

466.8K

Market Cap

$24.75M

About Longeveron Inc. Common Stock

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 38 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$137.0K	$-7,221,000	$-0.39
Q1 2025	$381.0K	$-5,011,000	$-0.34
FY 2024	$2.39M	$-15,973,000	$-2.62
Q3 2024	$773.0K	$-4,419,000	$-0.34

Related Market News

No specific coverage for LGVN yet. Check out our latest market news or earnings calendar.

Get LGVN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Longeveron Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.